ViiV, GSK and Pfizer’s HIV joint venture, has partnered with Russia’s JSC Binnopharm to boost manufacturing capacity in the country. The deal extends GSK and Binnopharm's manufacturing pact for GSK range of cervical cancer, pneumoncoccal and rotavirus vaccines.
ViiV teams with Russian manufacturer.
The deal is another example of the recent trend of Western pharma manufacturers partnering with Russian firms to manufacture products in Russia in accordance with the government's Pharma 20-20 plan. The plan calls for increased investment in Russian manufacturing capability and creation of more highly skilled jobs to support the growth of a local Russian pharma industry to more international standards. The ViiV partners plan full manufacturing transfer of core antiretroviral products from overseas to the Russian Federation.
Independently, Pfizer has further bolstered its Russian manufacturing presence through a deal with Petrovax Pharm. Petrovax will make Pfizer's pneumococcal vaccine. One can expect more of these deals in alignment with Russian goverment priorities -- especially if one plans to grow sales in this pharmerging market.
Posted by Bruce Lehr Nov 3rd 2011.
Comments